A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Tazarotene/ulobetasol (Primary) ; Tazarotene; Ulobetasol
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 08 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.